Rheumatic immune-related adverse events associated with immune checkpoint inhibitors: recognition, risk-stratified management, and long term follow-up

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause rheumatic immune-related adverse events (irAEs), ranging from inflammatory arthritis and polymyalgia rheumatica-like disease to life-threatening myositis overlap syndromes, vasculitis, and giant cell arteritis-like disease. Their heterogeneous clinical presentations, potential chronicity, and implications for anticancer treatment complicate clinical decision-making. This review summarizes current evidence on the recognition, initial risk stratification, major clinical phenotypes, and risk-adapted management of ICI-associated rheumatic irAEs. We discuss glucocorticoid use and tapering, glucocorticoid-sparing therapy, and individualized decisions regarding ICI continuation, interruption, discontinuation, and rechallenge. Long-term follow-up should integrate inflammatory disease activity, physical function, treatment-related toxicity, ICI treatment continuity, and oncologic outcomes. Multidisciplinary management is essential to balance adequate control of inflammation with preservation of anticancer benefit. Future studies should establish standardized diagnostic criteria, phenotype-specific treatment strategies, prospective risk-prediction models, and validated long-term outcome measures.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-17
DOI
https://doi.org/10.3389/fonc.2026.1956758
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors: recognition, risk-stratified management, and long term follow-up

Yuhan Zhang, Mingwei Li, Yiyao Huo, Zhiqiang Li
1 links
Frontiers in Oncology
Cancer Immunotherapy and Biomarkers
article

Rheumatic immune-related adverse events associated with immune checkpoint inhibitors: recognition, risk-stratified management, and long term follow-up

Yuhan Zhang, Mingwei Li, Yiyao Huo, Zhiqiang Li
article en

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can cause rheumatic immune-related adverse events (irAEs), ranging from inflammatory arthritis and polymyalgia rheumatica-like disease to life-threatening myositis overlap syndromes, vasculitis, and giant cell arteritis-like disease. Their heterogeneous clinical presentations, potential chronicity, and implications for anticancer treatment complicate clinical decision-making. This review summarizes current evidence on the recognition, initial risk stratification, major clinical phenotypes, and risk-adapted management of ICI-associated rheumatic irAEs. We discuss glucocorticoid use and tapering, glucocorticoid-sparing therapy, and individualized decisions regarding ICI continuation, interruption, discontinuation, and rechallenge. Long-term follow-up should integrate inflammatory disease activity, physical function, treatment-related toxicity, ICI treatment continuity, and oncologic outcomes. Multidisciplinary management is essential to balance adequate control of inflammation with preservation of anticancer benefit. Future studies should establish standardized diagnostic criteria, phenotype-specific treatment strategies, prospective risk-prediction models, and validated long-term outcome measures.

Frontiers in OncologyVol. 16
Capital Medical University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon